Hummingbird Diagnostics GmbH
Next generation of molecular blood tests Analysis of tumor and immune biomarkers
Main Info
Homepage
Homepage
Detecting disease early for tomorrow’s health.
LinkedIn
LinkedIn
Hummingbird Diagnostics GmbH | 1.162 Follower:innen auf LinkedIn. Harnessing the predictive power of blood-borne miRNAs | Hummingbird extracts deep insights into disease through the integrated analysis of both disease and immune system derived small RNA biomarkers from whole blood. This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases.
Address / GoogleMaps Location
Im Neuenheimer Feld 583, Heidelberg
Address / GoogleMaps Location
Find local businesses, view maps and get driving directions in Google Maps.
Tools
miR-Blood - A small RNA atlas of human blood components
miR-Blood - A small RNA atlas of human blood components
TransfoRNA - Navigating the Uncertainties of Small RNA Annotation with an Adaptive Machine Learning Strategy
TransfoRNA - Navigating the Uncertainties of Small RNA Annotation with an Adaptive Machine Learning Strategy
Publications - Lung Cancer
[2023 - miLung] Early Detection of Lung Cancer using small RNAs
[2023 - miLung] Early Detection of Lung Cancer using small RNAs
Lung cancer remains the deadliest cancer in the world, and lung cancer survival is heavily dependent on tumor stage at the time of detection. Low-dose computed tomography screening can reduce mortality; however, annual screening is limited by low adherence in the United States of America and still not broadly implemented in Europe. As a result, less than 10% of lung cancers are detected through existing programs. Thus, there is a great need for additional screening tests, such as a blood test, that could be deployed in the primary care setting.
[2022, miRisk 2] A blood-based miRNA complementary diagnostic predicts immunotherapy efficacy in advanced stage NSCLC with PD-L1 TPS ≥50%
[2022, miRisk 2] A blood-based miRNA complementary diagnostic predicts immunotherapy efficacy in advanced stage NSCLC with PD-L1 TPS ≥50%
[2022, miRisk 1] A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy - npj Precision Oncology
[2022, miRisk 1] A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy - npj Precision Oncology
Publications - Alzheimer's Disease
[2022, Alzheimer] LP48- Early Detection of Alzheimer's Disease Using microRNAs
[2022, Alzheimer] LP48- Early Detection of Alzheimer's Disease Using microRNAs
Publications - Tools
[2024, TransfoRNA] TransfoRNA: Navigating the Uncertainties of Small RNA Annotation with an Adaptive Machine Learning Strategy
[2024, TransfoRNA] TransfoRNA: Navigating the Uncertainties of Small RNA Annotation with an Adaptive Machine Learning Strategy
[2024, miR-Blood] miR-Blood – a small RNA atlas of human blood components
[2024, miR-Blood] miR-Blood – a small RNA atlas of human blood components
View on mobile
✕
